RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All WHO updates
WHO
REGULATORY UPDATE
Microlab’s Abacavir (as sulfate)/Dolutegravir (as sodium)/Lamivudine Dispersible Tablet, 60 mg/5 mg/30 mg prequalified
Published: 5/25/2026Detected: 4/10/2026

Summary preview

WHO Prequalification Unit (PQT) added the below new product to its prequalified list: • HA809 Abacavir (as sulfate)/Dolutegravir (as sodium)/Lamivudine Dispersible Tablet, 60 mg/5 mg/30 mg – Microlabs - INDIA.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account

Official Source Document
Source Verified

Access the original document directly from WHO.

View Official Document

More from WHO

  • New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/2/2026
  • PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/2/2026
  • PQ Webinar: Launch of WHO Prequalification of Medical Devices10/2/2026
  • New EUL listing10/2/2026
  • Prequalification of In Vitro Diagnostics: Scope Expansion10/2/2026

Get WHO alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.